Premium
Gabapentin in refractory partial epilepsy — a trial in India
Author(s) -
Dixit S. N.,
Jain S.,
Padma M. V.,
Maheshwari M. C.
Publication year - 1996
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1996.tb00179.x
Subject(s) - gabapentin , refractory (planetary science) , medicine , epilepsy , adverse effect , partial epilepsy , partial seizures , anesthesia , clinical trial , psychiatry , astrobiology , physics , alternative medicine , pathology
Gabapentin (GBP) has been shown to be effective an add‐on drug for the treatment of refractory partial epilepsy. We undertook an open clinical trial to test its efficacy for the first time in India. Twenty‐six patients with refractory partial seizures (> 4 per month) were given GBP in a titrated dose and the seizure frequency was noted for 3 months. The mean reduction in seizures was significant: 15.87 (SD = 4.5) vs 5.80 (SD = 10.25). The mean percentage change (PCH) from the baseline was ‐ 36. Twenty‐one of 26 (80%) patients had a reduction in the number of seizures, and 13/26 (50%) were identified as responders (> 50% reduction in seizures). The responders were significantly younger than the nonresponders. Adverse events were mild and noted in 46% patients. Although the trial has its limitations, this is probably the first trial of GBP in a developing country.